ubrogepant (Ubrelvy)
Jump to navigation
Jump to search
Indications
* 22% effective
* when taken during the prodrome phase, ubrogepant decreases likelihood of moderate to severe migraine[4]
Dosage
- 50 mg & 100 mg PO
Pharmacokinetics
- gepants able to cross the blood brain barrier
Adverse effects
Mechanism of action
- CGRP receptor antagonist
- gepants do not cause vasoconstriction
More general terms
References
- ↑ George J. Oral CGRP Inhibitor Helps Relieve Migraine Attack About 20% report being pain-free within 2 hours. MedPage Today. April 26, 2018 https://www.medpagetoday.com/meetingcoverage/aan/72559
Trugman J, et al Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: Results from a single attack phase II Study, ACHIEVE I. American Academy of Neurology (AAN) 2018. - ↑ FDA News Release. Dec 23, 2019 FDA approves new treatment for adults with migraine. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-migraine
- ↑ 3.0 3.1 Windle ML Rapid Rx Quiz: Headache Medications Medscape. Sept 12, 2022 https://reference.medscape.com/viewarticle/980181
- ↑ 4.0 4.1 Dodick DW, Goadsby PJ, Schwedt TJ et al. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. Lancet. 2023 Nov 15:S0140-6736(23)01683-5. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37979595 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01683-5/fulltext
- ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION UBRELVY (ubrogepant) tablets, https://media.allergan.com/products/Ubrelvy_pi.pdf